PL2697207T3 - Pochodne 3-(2-arylocykloalkenylometylo)oksazolidyn-2-onu jako inhibitory białka transportującego estry cholesterolu (cetp) - Google Patents
Pochodne 3-(2-arylocykloalkenylometylo)oksazolidyn-2-onu jako inhibitory białka transportującego estry cholesterolu (cetp)Info
- Publication number
- PL2697207T3 PL2697207T3 PL12770951T PL12770951T PL2697207T3 PL 2697207 T3 PL2697207 T3 PL 2697207T3 PL 12770951 T PL12770951 T PL 12770951T PL 12770951 T PL12770951 T PL 12770951T PL 2697207 T3 PL2697207 T3 PL 2697207T3
- Authority
- PL
- Poland
- Prior art keywords
- cycloalkenylmethyl
- cetp
- oxazolidin
- inhibitors
- aryl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
- C07D263/08—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D263/16—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D263/18—Oxygen atoms
- C07D263/20—Oxygen atoms attached in position 2
- C07D263/24—Oxygen atoms attached in position 2 with hydrocarbon radicals, substituted by oxygen atoms, attached to other ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/421—1,3-Oxazoles, e.g. pemoline, trimethadione
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
- C07D263/08—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D263/16—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
- C07D263/08—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D263/16—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D263/18—Oxygen atoms
- C07D263/20—Oxygen atoms attached in position 2
- C07D263/22—Oxygen atoms attached in position 2 with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to other ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/08—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing alicyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR20110033943 | 2011-04-12 | ||
| EP12770951.7A EP2697207B1 (en) | 2011-04-12 | 2012-04-12 | 3-(2-aryl-cycloalkenylmethyl)-oxazolidin-2-one derivatives as cholesterol ester transfer protein (cetp) inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL2697207T3 true PL2697207T3 (pl) | 2017-08-31 |
Family
ID=47009830
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL12770951T PL2697207T3 (pl) | 2011-04-12 | 2012-04-12 | Pochodne 3-(2-arylocykloalkenylometylo)oksazolidyn-2-onu jako inhibitory białka transportującego estry cholesterolu (cetp) |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US9371294B2 (pl) |
| EP (1) | EP2697207B1 (pl) |
| JP (1) | JP5820056B2 (pl) |
| KR (1) | KR101442644B1 (pl) |
| CN (1) | CN103502226B (pl) |
| AU (1) | AU2012243583B2 (pl) |
| CA (1) | CA2829676C (pl) |
| DK (1) | DK2697207T3 (pl) |
| ES (1) | ES2617221T3 (pl) |
| HR (1) | HRP20170422T1 (pl) |
| HU (1) | HUE032075T2 (pl) |
| MX (1) | MX342104B (pl) |
| PL (1) | PL2697207T3 (pl) |
| PT (1) | PT2697207T (pl) |
| RU (1) | RU2597266C2 (pl) |
| WO (1) | WO2012141487A2 (pl) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2627361C2 (ru) | 2013-01-31 | 2017-08-07 | Чонг Кун Данг Фармасьютикал Корп. | Биарил- или гетероциклические биарилзамещенные производные циклогексена в качестве ингибиторов сетр |
| CN107534722B (zh) * | 2015-03-31 | 2019-09-20 | 华为技术有限公司 | 一种终端设备和拍照的方法 |
| CN107304174B (zh) * | 2016-04-21 | 2019-05-10 | 沈阳药科大学 | N,n-双取代环烯基甲胺类衍生物及其制备方法和应用 |
| US20180072718A1 (en) | 2016-09-09 | 2018-03-15 | Incyte Corporation | Pyrazolopyridine compounds and uses thereof |
| AU2017322427B2 (en) | 2016-09-09 | 2021-12-23 | Incyte Corporation | Pyrazolopyridine derivatives as HPK1 modulators and uses thereof for the treatment of cancer |
| AR109595A1 (es) | 2016-09-09 | 2018-12-26 | Incyte Corp | Compuestos de pirazolopirimidina y usos de estos como inhibidores de hpk1 |
| US20180228786A1 (en) | 2017-02-15 | 2018-08-16 | Incyte Corporation | Pyrazolopyridine compounds and uses thereof |
| US10722495B2 (en) | 2017-09-08 | 2020-07-28 | Incyte Corporation | Cyanoindazole compounds and uses thereof |
| PL3755703T3 (pl) | 2018-02-20 | 2022-11-07 | Incyte Corporation | Pochodne n-(fenylo)-2-(fenylo)pirymidyno-4-karboksyamidu i związki pokrewne jako inhibitory hpk1 do leczenia nowotworu |
| WO2019164847A1 (en) | 2018-02-20 | 2019-08-29 | Incyte Corporation | Indazole compounds and uses thereof |
| US10745388B2 (en) | 2018-02-20 | 2020-08-18 | Incyte Corporation | Indazole compounds and uses thereof |
| SG11202008560VA (en) | 2018-03-08 | 2020-10-29 | Incyte Corp | AMINOPYRAZINE DIOL COMPOUNDS AS PI3K-y INHIBITORS |
| US11299473B2 (en) | 2018-04-13 | 2022-04-12 | Incyte Corporation | Benzimidazole and indole compounds and uses thereof |
| US11046658B2 (en) | 2018-07-02 | 2021-06-29 | Incyte Corporation | Aminopyrazine derivatives as PI3K-γ inhibitors |
| CN110759860B (zh) * | 2018-07-27 | 2022-10-14 | 江苏瑞科医药科技有限公司 | 一种3-甲酸甲酯-4-甲氧基-5-氰基吡啶的制备方法 |
| US10899755B2 (en) | 2018-08-08 | 2021-01-26 | Incyte Corporation | Benzothiazole compounds and uses thereof |
| MA53726A (fr) | 2018-09-25 | 2022-05-11 | Incyte Corp | Composés pyrazolo[4,3-d]pyrimidine en tant que modulateurs des alk2 et/ou fgfr |
| CA3147918A1 (en) | 2019-08-06 | 2021-02-11 | Incyte Corporation | Solid forms of an hpk1 inhibitor |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5929094A (en) | 1996-10-25 | 1999-07-27 | Merck & Co., Inc. | Heteroaryl spiroethercycloalkyl tachykinin receptor antagonists |
| JP2894445B2 (ja) | 1997-02-12 | 1999-05-24 | 日本たばこ産業株式会社 | Ｃｅｔｐ活性阻害剤として有効な化合物 |
| MXPA03009935A (es) | 2001-04-30 | 2004-01-29 | Pfizer Prod Inc | Metodos e intermedios para preparar inhibidores 4-aminoquinolina de cetp. |
| DOP2005000123A (es) * | 2004-07-02 | 2011-07-15 | Merck Sharp & Dohme | Inhibidores de cetp |
| RU2513107C2 (ru) | 2005-12-30 | 2014-04-20 | Мерк Шарп И Доум Корп. | Ингибиторы сетр |
| EP1971595B1 (en) * | 2005-12-30 | 2013-10-16 | Merck Sharp & Dohme Corp. | Cetp inhibitors |
| WO2007081570A2 (en) * | 2005-12-30 | 2007-07-19 | Merck & Co., Inc. | Cholesteryl ester transfer protein inhibitors |
| EP2136637B1 (en) * | 2007-03-16 | 2015-11-11 | Concert Pharmaceuticals, Inc. | Inhibitors of cholesterol ester transfer protein |
| GB2463788B (en) | 2008-09-29 | 2010-12-15 | Amira Pharmaceuticals Inc | Heteroaryl antagonists of prostaglandin D2 receptors |
| WO2010039474A1 (en) * | 2008-10-01 | 2010-04-08 | Merck Sharp & Dohme Corp. | Prodrugs of oxazolidinone cetp inhibitors |
-
2012
- 2012-04-12 CN CN201280017898.2A patent/CN103502226B/zh not_active Expired - Fee Related
- 2012-04-12 AU AU2012243583A patent/AU2012243583B2/en not_active Ceased
- 2012-04-12 EP EP12770951.7A patent/EP2697207B1/en active Active
- 2012-04-12 PT PT127709517T patent/PT2697207T/pt unknown
- 2012-04-12 ES ES12770951.7T patent/ES2617221T3/es active Active
- 2012-04-12 HU HUE12770951A patent/HUE032075T2/en unknown
- 2012-04-12 CA CA2829676A patent/CA2829676C/en active Active
- 2012-04-12 PL PL12770951T patent/PL2697207T3/pl unknown
- 2012-04-12 MX MX2013011855A patent/MX342104B/es active IP Right Grant
- 2012-04-12 JP JP2014505076A patent/JP5820056B2/ja active Active
- 2012-04-12 DK DK12770951.7T patent/DK2697207T3/en active
- 2012-04-12 RU RU2013145418/04A patent/RU2597266C2/ru active
- 2012-04-12 KR KR20120037886A patent/KR101442644B1/ko active IP Right Grant
- 2012-04-12 WO PCT/KR2012/002739 patent/WO2012141487A2/en active Application Filing
- 2012-04-12 US US14/110,271 patent/US9371294B2/en active Active
-
2017
- 2017-03-15 HR HRP20170422TT patent/HRP20170422T1/hr unknown
Also Published As
| Publication number | Publication date |
|---|---|
| HRP20170422T1 (hr) | 2017-06-16 |
| CN103502226A (zh) | 2014-01-08 |
| JP5820056B2 (ja) | 2015-11-24 |
| EP2697207A2 (en) | 2014-02-19 |
| CA2829676A1 (en) | 2012-10-18 |
| EP2697207B1 (en) | 2016-12-14 |
| US9371294B2 (en) | 2016-06-21 |
| AU2012243583B2 (en) | 2015-10-22 |
| ES2617221T3 (es) | 2017-06-15 |
| DK2697207T3 (en) | 2017-03-27 |
| US20140031335A1 (en) | 2014-01-30 |
| RU2597266C2 (ru) | 2016-09-10 |
| WO2012141487A2 (en) | 2012-10-18 |
| RU2013145418A (ru) | 2015-05-20 |
| PT2697207T (pt) | 2017-02-14 |
| CA2829676C (en) | 2017-08-22 |
| NZ615071A (en) | 2015-05-29 |
| MX2013011855A (es) | 2013-11-01 |
| KR20120116362A (ko) | 2012-10-22 |
| HUE032075T2 (en) | 2017-08-28 |
| MX342104B (es) | 2016-09-13 |
| EP2697207A4 (en) | 2014-11-19 |
| JP2014510786A (ja) | 2014-05-01 |
| WO2012141487A3 (en) | 2013-01-10 |
| AU2012243583A1 (en) | 2013-10-03 |
| US20150119376A2 (en) | 2015-04-30 |
| KR101442644B1 (ko) | 2014-09-19 |
| CN103502226B (zh) | 2015-08-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PL2697207T3 (pl) | Pochodne 3-(2-arylocykloalkenylometylo)oksazolidyn-2-onu jako inhibitory białka transportującego estry cholesterolu (cetp) | |
| EP2699293B8 (en) | Autoinjector apparatus | |
| ZA201306175B (en) | Isoxazole derivatives | |
| HK1201517A1 (en) | Process for preparing quinoline derivatives | |
| EP2725947A4 (en) | FLOOR STAND | |
| IL227664A0 (en) | New heterocyclic histories | |
| IL247642B (en) | History of isoxazole | |
| AU338702S (en) | Serving tray | |
| EP2799376A4 (en) | Arced-passage transfer apparatus | |
| EP2669574A4 (en) | COMBUSTION DEVICE FOR HEATING AN OVEN | |
| EP2744788A4 (en) | Benzopiperazine derivatives as CETP inhibitors | |
| LU91844B1 (en) | Charging device for shaft furnace | |
| EP3095777B8 (en) | Linezolid intermediate and method for synthesizing linezolid | |
| AP2014007697A0 (en) | Quinoline derivatives as PDE1OA enzyme inhibitors | |
| EP2673387A4 (en) | Direct smelting process | |
| EP2755663A4 (en) | INHIBITORS OF MICRO-ARNMICRORNA INHIBITORS | |
| EP2711416A4 (en) | METHOD FOR DESTRUCTION OF MICROORGANISM | |
| EP2739738A4 (en) | USE OF INTEGRASE FOR TARGETED GENE EXPRESSION | |
| PL2482017T3 (pl) | Instalacja do suszenia produktów | |
| HU4188U (en) | Arrangement for developing improved effected biogas | |
| ZA201401460B (en) | Method for cloning microbial genes | |
| AU2011904413A0 (en) | Heating Apparatus | |
| AU2011902350A0 (en) | Heating Apparatus | |
| AU2011901788A0 (en) | Heating apparatus | |
| AU2011905368A0 (en) | Dosing regime for apolipoprotein formulations |